KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Cash & Equivalents (2016 - 2025)

NovoCure (NVCR) has disclosed Cash & Equivalents for 12 consecutive years, with $93.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 42.88% to $93.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $93.5 million through Dec 2025, down 42.88% year-over-year, with the annual reading at $93.5 million for FY2025, 42.88% down from the prior year.
  • Cash & Equivalents hit $93.5 million in Q4 2025 for NovoCure, down from $342.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $689.8 million in Q3 2021 to a low of $93.5 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $244.9 million across 5 years, with a median of $188.4 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 194.22% in 2021 and later plummeted 71.95% in 2025.
  • Year by year, Cash & Equivalents stood at $208.8 million in 2021, then tumbled by 44.77% to $115.3 million in 2022, then surged by 108.82% to $240.8 million in 2023, then plummeted by 32.0% to $163.8 million in 2024, then plummeted by 42.88% to $93.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for NVCR at $93.5 million in Q4 2025, $342.1 million in Q3 2025, and $149.6 million in Q2 2025.